We are committed to strategic growth through targeted product development.

Smart Immune actively pursues co-development opportunities that add significant value to its pipeline and are relevant to its areas of expertise: thymus-educated T-cell progenitor-derived cell and gene therapies, with an increasing range of applications including hematological malignancies, primary immune deficiencies, and immune-oncology.

Please direct business development inquiries to:

Smart Immune
Paris Biotech Santé
29, rue du Faubourg St Jacques
75 014 Paris